Administering Bispecifics to Patients with R/R MM
Key opinion leaders discuss how bispecifics are administered at their institutions.
EP: 1.Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Administering Bispecifics to Patients with R/R MM
EP: 3.Administering Teclistamab for R/R MM in an Outpatient Setting
EP: 4.Monitoring Patients With R/R MM for CRS and ICANS
EP: 5.Outpatient Management of Teclistamab for R/R MM
EP: 6.Advice for Clinicians Administering Bispecifics to Patients With R/R MM
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
